Reneural Technologies Secures £200,000 for Stroke Rehabilitation
On November 6th, 2024, Reneural Technologies Limited, previously known as CardioCrown, announced that it has successfully secured £200,000 in a pre-seed funding round. This round was led by SFC Capital and saw additional support from Innovate UK, which contributed £275,000 to help propel the company's mission forward. Based in Hatfield, UK, Reneural is dedicated to addressing the significant gap in effective and continuous rehabilitation solutions for stroke survivors. The company aims to not only enhance patient outcomes but also reduce clinician burnout while lowering healthcare costs. By facilitating early discharge from hospitals, improving patient engagement, and fostering compliance, Reneural is paving the way for more efficient remote care options.
With the fresh influx of capital, Reneural intends to expand its virtual reality (VR) therapy offerings and explore options for mental health support tailored specifically for stroke survivors.
The company's long-term objective is to establish itself as a leader in the neurorehabilitation space by employing innovative technologies to enhance patient experiences and outcomes while alleviating pressure on healthcare systems. Ed Stevenson, an Investment Executive at SFC Capital, expressed excitement about leading the investment into Reneural, praising the founders' passion for tackling rehabilitation challenges. He noted that they look forward to witnessing the impact that the new VR products and mental health initiatives will have on improving the lives of stroke survivors.
Founded by Victor Harabari and Heraldas Gaspariunas, Reneural is poised to make significant strides in the neurotech industry. Victor, serving as CEO, brings a strong background in biomedical engineering and medical devices to the table. Meanwhile, Heraldas, as COO, contributes essential operational leadership to help guide the company's vision. With substantial advances already made and a collaborative approach involving healthcare professionals, Reneural plans to carry out its first clinical investigations in January 2025. These studies will be supported by the HTCC SME Accelerators, in partnership with the University of Hertfordshire. As the company continues to innovate and expand its offerings, it remains committed to delivering a comprehensive neurorehabilitation platform that integrates cutting-edge technologies for personalized long-term care.
They've invested in Reneural
Get to know these Healthtech investors
Click here for a full list of 6,528+ startup investors in the UK